Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397977 | 0.88 | HDAC1 (0.68) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3779070 | 0.88 | HDAC1 (0.74) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3771409 | 0.87 | HDAC1 (0.76) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3643999 | 0.86 | HDAC1 (0.72) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3774980 | 0.84 | HDAC1 (0.72) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1067101 | 0.84 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL4579961 | 0.84 | HDAC1 (0.75) | HDAC1HDAC2HDAC3 | |
| SCHEMBL4796266 | 0.84 | HDAC1 (0.64) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3771063 | 0.83 | HDAC1 (0.71) | HDAC1HDAC2HDAC3 | |
| SCHEMBL2688286 | 0.83 | HDAC1 (0.79) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | claimed |
| EP-2170076-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009002495-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | claimed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC4, HDAC5 | HDAC1 5/4885HDAC2 6/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.